’¼üã‚É”z’u


2007”N‚ÌŠˆ“®


š‘æ55‰ñ@“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïš
` 10ŒŽ 21-23“úEŽD–yƒRƒ“ƒxƒ“ƒVƒ‡ƒ“ƒZƒ“ƒ^[CŽD–y `

uHIV-1×–E“àN“ü‚É‚¨‚¯‚éERMƒtƒ@ƒ~ƒŠ[’`”’Ž¿‚ÌŠÖ—^v
‹v•Û‰Ã’¼C@‹g‹œA˜NC@_ŽR—zC@“c’†—E‰xC
²“¡—T“¿C@ŽR–{’¼Ž÷

uƒGƒ“ƒhƒTƒCƒg[ƒVƒX‘jŠQÜ‚ÌCD4”ñˆË‘¶«HIV-1Š´õ‚ɑ΂·‚é‰e‹¿v
‹g‹œA˜NC@_ŽR—zC@²“¡—T“¿C@ŽR–{’¼Ž÷C@‹v•Û‰Ã’¼

uHIV-1Š´õ‚É‚¨‚¯‚é–Œ— ‘Å‚¿ƒ^ƒ“ƒpƒNŽ¿‚ÌŠÖ—^GRNAi‚É‚æ‚é–Ô—…“I‰ðÍv
_ŽR—zC@‹g‹œA˜NC@²“¡—T“¿C@ŽR–{’¼Ž÷C@‹v•Û‰Ã’¼




2006”N‚ÌŠˆ“®


š‘æ17”N“x@‘æ1‰ñ‡“¯”ljï‹cš
(Œú¶˜J“­È‰ÈŠwŒ¤‹†”ï•â•‹àƒGƒCƒY‘΍ôŒ¤‹†Ž–‹Æ)
` 1ŒŽ 24-26“úE‘—§Š´õÇŒ¤‹†ŠCVh `

uHIV-1Š´õ‚É‚¨‚¯‚éERMƒtƒ@ƒ~ƒŠ[’`”’Ž¿‚ÌŠÖ—^v

‹v•Û‰Ã’¼


š‹ž“s‘åŠwƒEƒCƒ‹ƒXŒ¤‹†Š‘n—§50Žü”N‹L”O‘ÛƒVƒ“ƒ|ƒWƒEƒ€E
‘æ‚Q‰ñŒ¤‹†Šƒlƒbƒgƒ[ƒN‘ÛƒVƒ“ƒ|ƒWƒEƒ€@‡“¯ƒVƒ“ƒ|ƒWƒEƒ€ š
` 5ŒŽ 29-31“úE‹ž“s‘åŠwˆãŠw•”ŽÅ—–‰ïŠÙC‹ž“s `

‹g‹œA˜N


š‘æ54‰ñ@“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïš
` 11ŒŽ 19-21“úE–¼ŒÃ‰®‘Û‰ï‹cêC–¼ŒÃ‰® `

uCXCR4“œ½Cü‚É‚æ‚éHIV-1Š´õ–hŒä‚ƁA‚»‚̉ñ”ð‹@\v
‹v•Û‰Ã’¼C@‰¡ŽR@ŸC@‹g‹œA˜NC@_ŽR—zC@“c’†—E‰xC
²“¡—T“¿C@ŽR–{’¼Ž÷

uHeLa×–E‚É‚¨‚¯‚éCD4”ñˆË‘¶«HIV-1‚̍זEN“ü—}§‹@\v
‹g‹œA˜NC@_ŽR—zC@‘åÎ˜a“¿C@“c’†—E‰xC@²“¡—T“¿C
ŽR–{’¼Ž÷C@‹v•Û‰Ã’¼

uƒrƒ^ƒ~ƒ“A—ÞŽ—‘ÌGeranylgeranoic acid (GGA) ‚É‚æ‚éHIV-1Š´õ‚Ì—}§v
_ŽR—zC@‹g‹œA˜NC@“c’†—E‰xC@²“¡—T“¿C
ŽR–{’¼Ž÷C@Žl“¶ŽqDœAC@‹v•Û‰Ã’¼




2005”N‚ÌŠˆ“®


š‘æ42‰ñ@“ú–{ƒEƒCƒ‹ƒXŠw‰ï‹ãBŽx•”‘‰ïš
` 7ŒŽ 7-9“úE‰«“ꏗ«‘‡ƒZƒ“ƒ^[u‚Ä‚¡‚é‚évC“ß”e `

uCXCR4“œ½Cü‚É‚æ‚éCD4”ñˆË‘¶«HIV-1Š´õ‚Ì—}§v

‹v•Û‰Ã’¼C@‹g‹œA˜NC@“c’†—E‰xC@²“¡—T“¿C@ŽR–{’¼Ž÷

u“¯ŽíŽwŒü«ƒ}ƒEƒXƒŒƒgƒƒEƒCƒ‹ƒX‚̏hŽåˆæŒˆ’è‹@\‚̉𖾁v
‹g‹œA˜NC@‘åÎ˜a“¿C@“VÀGC@ŽR–{’¼Ž÷C@‹v•Û‰Ã’¼


š‹¤“¯Œ¤‹†@‹ZpK“¾š
` 9ŒŽ 12-16“úE—‰»ŠwŒ¤‹†ŠE’†‰›Œ¤‹†ŠC˜aŒõ `

uVirus Env - Receptor binding assayv

‹g‹œA˜N


š‘æ53‰ñ@“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïš
` 11ŒŽ 20-22“úEƒpƒVƒtƒBƒR‰¡•lC‰¡•l `

uHIV-1‚̍זEN“ü‚É‚¨‚¯‚éƒGƒYƒŠƒ“‚ÌŠÖ—^v

‹v•Û‰Ã’¼C@‹g‹œA˜NC@“c’†—E‰xC@²“¡—T“¿C@ŽR–{’¼Ž÷

uMus dunni ×–EŠ”‚Ì“¯ŽíŽwŒü«ƒ}ƒEƒX”’ŒŒ•aƒEƒCƒ‹ƒX
Š´õ’ኴŽó«‚ÌŒˆ’è‹@\v

‹g‹œA˜NC@‘åÎ˜a“¿C@ŽR–{’¼Ž÷C@‹v•Û‰Ã’¼


š‹¤“¯Œ¤‹†‰ïš
` 12ŒŽ 22“úE’·è‘åŠw”M‘шãŠwŒ¤‹†ŠE“–Œ¤‹†ŽºC’·è `

“VÀGæ¶C@‹{ìŒh‚³‚ñC@‹v•Û‰Ã’¼C
‹g‹œA˜NC@_ŽR—zC@“cŒû³„iˆãŠw•”3”Nj




2004”N‚ÌŠˆ“®


šƒŒƒgƒƒEƒCƒ‹ƒXŒ¤‹†‰ï@‰Ä‹GƒZƒ~ƒi[š
` 6ŒŽ4-6“úE¶–½‚̐XƒŠƒ][ƒg@“ú–{ƒGƒAƒƒrƒNƒXƒZƒ“ƒ^[Cç—t `

uƒŒƒgƒƒEƒCƒ‹ƒX‚ƏhŽå‚Ì‹¤i‰»v

‹v•Û‰Ã’¼


š16th International Workshop on Retroviral Pathogenesisš
` 10ŒŽ 27-31“ú Holiday Inn Midtown Hotel, Montreal, Canada`

uDeterminant for the inhibition of ecotropic murine leukemia virus
infection by N-linked glycosylation of the rat receptor.v

Hiroaki Yoshii, Akinori Ishimoto, Takeshi Ono, Chika Tominaga,
Chiho Mitani, Hiroshi Amanuma, Naoki Yamamoto, and Yoshinao Kubo


š‘æ52‰ñ@“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïš
` 11ŒŽ 21-23“úEƒpƒVƒtƒBƒR‰¡•lC‰¡•l `

uCD4”ñˆË‘¶«HIV-1Š´õ‚É‚¨‚¯‚郉ƒtƒg‚Ì–ðŠ„v

‹v•Û‰Ã’¼C@‹g‹œA˜NC@“c’†—E‰xC@²“¡—T“¿C@ŽR–{’¼Ž÷


ƒgƒbƒv ƒAƒCƒRƒ“

’¼üã‚É”z’u